Cargando…

New Modulators for IGF-I Activity within IGF-I Processing Products

Insulin-like growth factor I (IGF-I) is a key regulator of muscle development and growth. The pre-pro-peptide produced by the Igf1 gene undergoes several post-translational processing steps to result in a secreted mature protein, which is thought to be the obligate ligand for the IGF-I receptor (IGF...

Descripción completa

Detalles Bibliográficos
Autores principales: Brisson, Becky K., Barton, Elisabeth R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3608916/
https://www.ncbi.nlm.nih.gov/pubmed/23543904
http://dx.doi.org/10.3389/fendo.2013.00042
_version_ 1782264287281020928
author Brisson, Becky K.
Barton, Elisabeth R.
author_facet Brisson, Becky K.
Barton, Elisabeth R.
author_sort Brisson, Becky K.
collection PubMed
description Insulin-like growth factor I (IGF-I) is a key regulator of muscle development and growth. The pre-pro-peptide produced by the Igf1 gene undergoes several post-translational processing steps to result in a secreted mature protein, which is thought to be the obligate ligand for the IGF-I receptor (IGF-IR). However, the significance of the additional forms and peptides produced from Igf1 is not clear. For instance, the C-terminal extensions called the E-peptides that are part of pro-IGF-I, have been implicated in playing roles in cell growth, including cell proliferation and migration and muscle hypertrophy in an IGF-IR independent manner. However, the activity of these peptides has been controversial. IGF-IR independent actions suggest the existence of an E-peptide receptor, yet such a protein has not been discovered. We propose a new concept: there is no E-peptide receptor, rather the E-peptides coordinate with IGF-I to modulate activity of the IGF-IR. Growing evidence reveals that the presence of an E-peptide alters IGF-I activity, whether as part of pro-IGF-I, or as a separate peptide. In this review, we will examine the past literature on IGF-I processing and E-peptide actions in skeletal muscle, address the previous attempts to separate IGF-I and E-peptide effects, propose a new model for IGF-I/E-peptide synergy, and suggest future experiments to test if the E-peptides truly modulate IGF-I activity.
format Online
Article
Text
id pubmed-3608916
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-36089162013-03-29 New Modulators for IGF-I Activity within IGF-I Processing Products Brisson, Becky K. Barton, Elisabeth R. Front Endocrinol (Lausanne) Endocrinology Insulin-like growth factor I (IGF-I) is a key regulator of muscle development and growth. The pre-pro-peptide produced by the Igf1 gene undergoes several post-translational processing steps to result in a secreted mature protein, which is thought to be the obligate ligand for the IGF-I receptor (IGF-IR). However, the significance of the additional forms and peptides produced from Igf1 is not clear. For instance, the C-terminal extensions called the E-peptides that are part of pro-IGF-I, have been implicated in playing roles in cell growth, including cell proliferation and migration and muscle hypertrophy in an IGF-IR independent manner. However, the activity of these peptides has been controversial. IGF-IR independent actions suggest the existence of an E-peptide receptor, yet such a protein has not been discovered. We propose a new concept: there is no E-peptide receptor, rather the E-peptides coordinate with IGF-I to modulate activity of the IGF-IR. Growing evidence reveals that the presence of an E-peptide alters IGF-I activity, whether as part of pro-IGF-I, or as a separate peptide. In this review, we will examine the past literature on IGF-I processing and E-peptide actions in skeletal muscle, address the previous attempts to separate IGF-I and E-peptide effects, propose a new model for IGF-I/E-peptide synergy, and suggest future experiments to test if the E-peptides truly modulate IGF-I activity. Frontiers Media S.A. 2013-03-27 /pmc/articles/PMC3608916/ /pubmed/23543904 http://dx.doi.org/10.3389/fendo.2013.00042 Text en Copyright © 2013 Brisson and Barton. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and subject to any copyright notices concerning any third-party graphics etc.
spellingShingle Endocrinology
Brisson, Becky K.
Barton, Elisabeth R.
New Modulators for IGF-I Activity within IGF-I Processing Products
title New Modulators for IGF-I Activity within IGF-I Processing Products
title_full New Modulators for IGF-I Activity within IGF-I Processing Products
title_fullStr New Modulators for IGF-I Activity within IGF-I Processing Products
title_full_unstemmed New Modulators for IGF-I Activity within IGF-I Processing Products
title_short New Modulators for IGF-I Activity within IGF-I Processing Products
title_sort new modulators for igf-i activity within igf-i processing products
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3608916/
https://www.ncbi.nlm.nih.gov/pubmed/23543904
http://dx.doi.org/10.3389/fendo.2013.00042
work_keys_str_mv AT brissonbeckyk newmodulatorsforigfiactivitywithinigfiprocessingproducts
AT bartonelisabethr newmodulatorsforigfiactivitywithinigfiprocessingproducts